Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/8/2025

HIV Testing Guidelines

Testing Schedule

  • The CDC recommends immediate testing using rapid antibody or rapid antigen-antibody test to rule out prior infection, and preferably use a 4th generation test for initial screening 1
  • The CDC recommends initial testing at baseline before starting PEP, and interim testing at 4-6 weeks after exposure using both laboratory-based HIV Ag/Ab test and diagnostic HIV NAT, with the 4-6 week test potentially deferred for individuals who started PEP within 24 hours of exposure, completed the full 28-day regimen, and are not considering PrEP 2
  • PEP should not be delayed while waiting for test results, as recommended by the American Academy of Family Physicians and the CDC 2, 1

Conclusive Testing

  • The CDC recommends final conclusive testing at 12 weeks after exposure using laboratory-based HIV Ag/Ab combination immunoassay and diagnostic HIV NAT for definitive results, representing an update from older guidelines that recommended testing for up to 6 months post-exposure 2, 3
  • Both laboratory-based Ag/Ab tests and NAT are required at the final testing point to maximize detection sensitivity, as antiretroviral medications taken as PEP can suppress HIV viral load, delay seroconversion, and decrease the ability to detect HIV infection 2
  • The window period for conclusively ruling out HIV infection extends beyond 45 days post-PEP completion, highlighting the need for both laboratory-based Ag/Ab tests and NAT to improve sensitivity for detecting HIV infection 2

Test Capabilities and Accuracy

  • Oral fluid-based rapid HIV tests are less sensitive for detecting acute or recent infection than blood tests, and are therefore not recommended for HIV detection in the context of PEP services 2
  • The use of laboratory-based Ag/Ab tests and NAT can improve sensitivity for detecting HIV infection, especially in individuals taking antiretroviral medications as PEP 2

Special Considerations

  • For patients transitioning from PEP to PrEP due to ongoing risk factors, HIV testing should be performed at the completion of the PEP regimen, and patients should be counseled about the possibility of false-negative results, with ongoing PrEP care and recommended HIV testing 2, 4
  • Individuals who start PrEP before the final HIV test at 12 weeks should be informed about the possibility of a false-negative result and the importance of ongoing PrEP care with recommended HIV testing 2, 4
  • It is essential to be aware of signs and symptoms of acute HIV infection, which can include flu-like illness, fever, night sweats, swollen or enlarged lymph nodes, muscle or joint pains, sore throat, fatigue, headache, rashes, or sores, and to test for other sexually transmitted infections, as any sexual exposure that poses a risk of HIV infection may also put an individual at risk of acquiring other infections 2, 4